In a report released yesterday, Allen Klee from Maxim Group reiterated a Buy rating on Cryo-Cell International (CCEL – Research Report), with a price target of $10.00. The company’s shares opened today at $4.50.
Klee covers the Technology sector, focusing on stocks such as Marpai, Interlink Electronics, and Research Solutions. According to TipRanks, Klee has an average return of -21.9% and a 22.58% success rate on recommended stocks.
Cryo-Cell International has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.12 and a one-year low of $2.69. Currently, Cryo-Cell International has an average volume of 9,514.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cryo-Cell International, Inc. is cord blood bank, which engages in providing stem cell cryopreservation service and to advance regenerative medicine. It operates through the following segments: Cellular Processing and Cryogenic Storage; and Prepacyte CB. The Cellular Processing and Cryogenic Storage segment focuses on the collection and preservation of umbilical cord blood and tissue stem cells for family use. The Prepacyte CB segment refers to the processing technology used to process umbilical cord blood stem cells. The company was founded on September 11, 1989 and is headquartered in Oldsmar, FL.
Read More on CCEL:
